Brimonidine tartrate ophthalmic solution is used to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Apotex is recalling six lots of Brimonidine Tartrate Ophthalmic Solution 0.15%, which is an alpha-adrenergic receptor agonist to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Cracks have been found in some of the units caps of brimonidine tartrate ophthalmic solution bottles. There is a possibility the broken cap may impact sterility and if so, the possibility of adverse events.
The lot number and expiration date are located on the top flap of the carton and to the left side of the product description on the bottle label beside the barcode. These lots were distributed nationwide in the USA between April 05, 2022, to February 22, 2023. Lot numbers and expiration dates are listed here.
FDA and EMA Accepts Applications for New Nusinersen Regimen
January 23rd 2025An investigational higher dose of spinal muscular atrophy drug nusinersen gains attention as the FDA and European Medicines Agency (EMA) considerate it as an alternative than the current lower FDA-approved dosage.
Read More